ArticleJTO clinical and research reports2026

Preoperative Immune-Related Adverse Events in Resectable NSCLC Treated With Neoadjuvant Nivolumab Plus Chemotherapy: A Multicenter Retrospective Analysis.

Takuya Watanabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.